Daewoong Pharmaceutical said Monday the company will develop a microneedle-based obesity treatment drug.

The South Korean pharmaceutical company aims to start a phase 1 clinical trial next year and launch the treatment in 2028.

Daewoong Pharmaceutical’s new obesity treatment will contain a synthetic peptide semaglutide, which is similar to glucagon-like peptide-1 (GLP-1), a hormone produced in the gut released in response to food to reduce appetite and the release of insulin.

The patch-type obesity treatment, measuring 1 square centimeter, will use drug-loaded dissolvable microneedles to penetrate the outer layer of the skin to deliver drug ingredients to the patient’s body. The company said patients will be able to easily administer the treatment and minimize injections-associated fears involving existing injection-type GLP-1 agonists.

“The patch-type obesity treatment will increase overall medication adherence of patients with obesity who have to take the treatment on a regular basis,” an official from Daewoong Pharmaceutical said. Daewoong Pharmaceutical said patients will need to use its patch-type obesity treatment just once a week.

Daewoong Pharmaceutical added the new treatment also aims to eliminate common side effects like skin swelling or lumps to improve the treatment experience.

For the development of the patch-type obesity treatment, Daewoong Pharmaceutical will also apply its own microneedle platform technology known as closed-packed aero-pressured microneedle (CLOPAM).

“While microneedles have been widely used in cosmetics, their application in medicine has been limited due to issues involving drug capacity and transdermal absorption. Daewoong Pharmaceutical’s CLOPAM technology is designed to ensure efficient drug delivery and minimize drug loss,” the official said.

Daewoong Pharmaceutical's microneedle platform technology will allow patients to store and use the treatment at room temperature, the official added.

Daewoong Pharmaceutical's microneedle platform has been developed by its research and development unit Daewoong Therapeutics. Daewoong Pharmaceutical has filed 23 patents in South Korea and registered six international patents for the microneedle technology. The company said it has received a proposal from a global pharmaceutical firm to develop other microneedle-based medications.

With the development of patch-type obesity treatment, Daewoong aims to enter the rapidly growing global obesity treatment market, it said. The global market for obesity treatments is expected to grow to 104 trillion won ($80 billion) by 2030, the firm said, quoting data from Morgan Stanley.

"Daewoong Pharmaceutical will push ahead with the development of the new patch-type obesity treatment for patients with unmet medical needs," Daewoong Pharmaceutical CEO Jeon Seung-ho said.

Meanwhile, Daewoong Pharmaceutical is also conducting studies to develop its new diabetes drug Enblo as a potential treatment for obesity.

• ·N. Korea reinstates DMZ guard posts
• ·S. Korea, US, Japan stage trilateral maritime interdiction drills for 1st time in 7 years
• ·Kia reaches tentative agreement with union
• ·[Our Museums] Discover wisdom of hanok at Eunpyeong History Hanok Museum
• ·Seoul shares open higher despite US losses
• ·[Herald Interview] Chile, Korea need to boost global lithium value chain: minister
• ·안철수 측 "심장이상? 허위" 장성철 "安 쓰러져 심폐소생술"
• ·US toughens rules on exports of advanced computing chips to China
• ·Former Hungarian ambassador receives Gwanghwa Medal
• ·Foreign workers' deaths get weak sanctions
• ·US strategic bomber B
• ·Biden says Hamas must be eliminated, US officials warn war could escalate
• ·[Korea Beyond Korea] Korean studies in Turkey grows on foundation of strong relations
• ·Response to Yasukuni visits underway: official
• ·S. Korean industries to see modest recovery in 2024: think tank
• ·S. Korea, Latin America to discuss ways to boost trade, ICT cooperation